Wyeth
Wyeth is a historic American pharmaceutical and nutrition company whose businesses and brands became part of Pfizer after its 2009 acquisition.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Wyeth was an American pharmaceutical and consumer-health company with roots in Philadelphia, where brothers John Wyeth and Frank Wyeth established a drug business in 1864. The company developed from a pharmacy and pharmaceutical manufacturer into one of the largest diversified healthcare groups in the United States. Its activities eventually covered prescription medicines, vaccines, over-the-counter products, nutritional products and consumer healthcare brands. The company operated for much of its modern history under the name American Home Products Corporation, commonly abbreviated AHP. Through acquisitions, internal research and product development, AHP assembled a broad portfolio spanning medicines, household healthcare products and nutritional businesses. The corporation later adopted the Wyeth name, reflecting the importance of the historic pharmaceutical business and helping create a more unified identity for its international operations. Wyeth’s pharmaceutical portfolio included major prescription and preventive-health products. Historical products associated with the company included Premarin, a conjugated-estrogens product; Effexor, an antidepressant later marketed as Effexor XR; Enbrel, an immunology medicine developed with Immunex; Prevnar, a pneumococcal conjugate vaccine; and a range of medicines in women’s health, neuroscience, inflammation and other therapeutic areas. The company also had significant consumer-health and nutrition operations, with brands and products such as Advil, Centrum and Robitussin associated with businesses acquired or operated during different periods of its corporate history. Wyeth was especially significant in infant and maternal nutrition. Its nutrition business marketed infant formula and related products under the Wyeth and other local or regional brand identities. That business had a substantial presence in China and other international markets. The nutrition operation was separated from Pfizer after the acquisition and sold to Nestlé in 2012. Consequently, the present-day use of the Wyeth name is not identical across all markets: some Wyeth pharmaceutical assets were integrated into Pfizer, while Wyeth nutrition products became part of Nestlé’s nutrition portfolio. Pfizer announced an agreement to acquire Wyeth in 2009, and the transaction closed later that year. The deal combined Pfizer’s pharmaceutical operations with Wyeth’s prescription, vaccine, biotechnology and consumer-health assets. After the transaction, Wyeth ceased to operate as an independent publicly traded corporation, although the Wyeth name continued to appear on selected products, legal entities and historical business lines. Pfizer has retained or used the Wyeth name in parts of its portfolio, while many individual products have been rebranded, integrated or discontinued over time. Wyeth is therefore best understood as both a historic pharmaceutical company and a continuing brand and corporate legacy within Pfizer. Its identity is also connected to the broader history of American Home Products, the growth of modern pharmaceutical research, the commercialization of vaccines and biologic medicines, and the international expansion of infant nutrition. Because ownership, product availability and brand usage vary by country and therapeutic area, individual Wyeth products should be evaluated according to their current local manufacturer and regulatory status.
History
Wyeth traces its origins to 1864, when brothers John and Frank Wyeth established a pharmaceutical business in Philadelphia. The early company operated in an era when drug manufacturing was becoming more standardized and pharmacists were increasingly producing medicines for wider distribution. Over time, the business expanded beyond its original pharmacy-based activities and became part of the consolidation of the American healthcare industry. During the twentieth century, the company developed and acquired operations in prescription medicines, consumer healthcare and nutrition. Its corporate identity for much of the modern period was American Home Products Corporation, generally known as AHP. AHP built a diversified healthcare portfolio through a combination of research, manufacturing and acquisitions. The group’s products covered medicines, vaccines, over-the-counter remedies, household healthcare products and nutritional goods, giving it a broader scope than a narrowly focused pharmaceutical research company. The Wyeth name became increasingly important as the corporation sought a more unified identity. The company was renamed Wyeth in 2002. By that point, its activities included pharmaceutical research and development, biotechnology, vaccines, consumer healthcare and nutrition. Its research portfolio included medicines in women’s health, neuroscience, inflammation and immunology, as well as products for preventive healthcare. The company’s commercial reach extended across North America, Europe, Asia and other international markets. Several products became closely associated with Wyeth. Premarin made the company a major participant in hormone therapy and women’s health, while Effexor became an important neuroscience product. Enbrel represented the company’s role in biologic medicines and inflammatory disease treatment. Prevnar established a major position in pneumococcal vaccination. Wyeth also operated or owned well-known consumer-health and nutrition activities, although the ownership history of brands such as Advil, Centrum and Robitussin changed as the company bought, sold or reorganized businesses. The company’s history also includes significant legal and regulatory controversy. Hormone-therapy products associated with Wyeth, including Premarin and Prempro, became the subject of litigation and public debate concerning health risks, labeling and promotion. These matters took place against the background of broader changes in medical evidence and regulatory guidance concerning menopausal hormone therapy. Wyeth and its predecessor American Home Products also faced disputes involving the promotion of certain consumer and dietary-supplement products. In 2009, Pfizer agreed to acquire Wyeth. The transaction was completed the same year and transformed Wyeth from an independent public company into a Pfizer business. The combination added Wyeth’s vaccines, biologics, prescription medicines, consumer-health operations and nutrition activities to Pfizer’s portfolio. Integration subsequently changed the structure and visibility of the Wyeth name. Some products continued under established names, some were placed under Pfizer management, and some businesses were later divested. In 2012, Nestlé acquired Pfizer’s infant-nutrition business. This transaction separated the nutrition operations associated with Wyeth from Pfizer’s remaining pharmaceutical and vaccine businesses. In markets where Nestlé retained Wyeth-related names, the brand became principally associated with infant formula and nutritional products rather than with the full range of medicines historically developed by Wyeth. Today, Wyeth is not an independent listed corporation. It remains an important historical pharmaceutical identity and continues to appear in selected product, business and legal contexts, particularly where Pfizer or Nestlé retains local rights to use the name. Product availability and ownership are market-specific, so the brand should be treated as a legacy healthcare house with different successor owners for different business lines.
- 2012
Nutrition business sold to Nestlé
[3]Nestlé completed its acquisition of Pfizer Nutrition, separating the former Wyeth nutrition business from Pfizer's remaining healthcare operations.
- 2009
Pfizer acquisition completed
[2]Pfizer completed its acquisition of Wyeth, ending Wyeth's existence as an independent public company.
- 2002
American Home Products adopts the Wyeth name
[1]American Home Products Corporation changed its corporate name to Wyeth, placing the historic pharmaceutical identity at the center of the group brand.
- 1864
Wyeth brothers establish the business
[1]John Wyeth and Frank Wyeth founded the Philadelphia pharmaceutical business that became the origin of Wyeth.
Products and positioning
A science-led healthcare company spanning prescription pharmaceuticals, vaccines, biotechnology, consumer health and nutrition. Following its acquisition by Pfizer, Wyeth is primarily a historical corporate identity and a product or business-line brand whose use differs by market.
Pneumococcal vaccine
Prevnar
Prevnar is a pneumococcal conjugate vaccine franchise historically developed and commercialized by Wyeth. It became one of the company’s most important preventive-health products and was subsequently integrated into Pfizer’s vaccine portfolio after the acquisition. Formulations and approved uses have changed over time and differ by market.
Biologic immunology medicine · 1998
Enbrel
Enbrel is a biologic medicine used for several inflammatory and autoimmune conditions. Wyeth was a major commercial partner and manufacturer associated with the product before the Pfizer acquisition. Rights, commercialization arrangements and market access have varied by territory, and the product is now associated with Pfizer in relevant markets.
Antidepressant · 1993
Effexor and Effexor XR
Effexor and the extended-release Effexor XR formulation are venlafaxine-based prescription medicines historically associated with Wyeth’s neuroscience business. They were widely used in the treatment of depressive and anxiety-related disorders. The products became part of Pfizer’s inherited portfolio after the acquisition, although patent, generic and local-market conditions have changed their commercial significance.
Women's-health hormone therapy · 1942
Premarin
Premarin is a conjugated-estrogens hormone-therapy product and one of the best-known medicines in Wyeth’s historical portfolio. It made Wyeth a prominent company in women’s health, while also exposing the company to substantial public debate, regulatory scrutiny and litigation concerning the benefits and risks of menopausal hormone therapy.
Infant formula and maternal nutrition
Wyeth infant nutrition
Wyeth’s nutrition business included infant formula, growing-up milk and related maternal or child-nutrition products sold under Wyeth and local-market brand identities. It was particularly important to the company’s international profile. Pfizer sold the nutrition operation to Nestlé in 2012, so current ownership and labeling depend on the country and product line.
Over-the-counter analgesic · 1984
Advil
Advil is an ibuprofen-based over-the-counter pain-relief brand associated with Wyeth’s historical consumer-health activities. The brand’s ownership and commercial arrangements have changed over time, and it should not be assumed that every Advil product or market is currently operated by Pfizer or carries a Wyeth corporate identity.
Vitamin and dietary supplement · 1978
Centrum
Centrum is a multivitamin and dietary-supplement brand that formed part of the broad consumer-health portfolio associated with Wyeth and American Home Products. It illustrates the company’s historical reach beyond prescription medicines. Later ownership and distribution arrangements have differed by market and corporate transaction.
Over-the-counter cough medicine
Robitussin
Robitussin is an over-the-counter cough and cold medicine brand historically connected with Wyeth’s consumer-health operations. Its products and ownership have changed through portfolio transactions, and the brand is now managed separately from Wyeth’s former independent corporate structure.
Controversies
2000
Dietary-supplement advertising dispute
American Home Products, later renamed Wyeth, reached a settlement with U.S. authorities concerning advertising claims for certain dietary-supplement products. The matter contributed to scrutiny of the company's consumer-health marketing practices.
Hormone-therapy litigation and regulatory controversy
Wyeth and its predecessor American Home Products faced extensive litigation and public scrutiny concerning Premarin, Prempro and related hormone-therapy products. The disputes addressed alleged health risks, product warnings and promotional practices, amid broader changes in medical evidence regarding menopausal hormone therapy.
Brand decisions
2012
Sell the infant-nutrition business to NestléM&ABackground
Pfizer reviewed its portfolio after acquiring Wyeth and received interest in the former Wyeth nutrition operations.
Action taken
Pfizer sold its infant-nutrition business to Nestlé.
Aftermath
The Wyeth nutrition legacy became associated with Nestlé in relevant markets, while Pfizer retained the pharmaceutical and vaccine businesses inherited from Wyeth.
2009
Pfizer acquires WyethM&ABackground
Wyeth owned significant prescription, vaccine, biologic, consumer-health and nutrition operations, while Pfizer sought broader scale and portfolio diversification.
Action taken
Pfizer agreed to acquire Wyeth and completed the transaction in 2009.
Aftermath
Wyeth ceased to be an independent listed company, and its businesses were integrated into Pfizer or later divested.
2002
Adopt the Wyeth corporate identityStrategyBackground
American Home Products operated a diversified healthcare portfolio under a name that did not directly reflect its pharmaceutical heritage.
Action taken
The corporation changed its name to Wyeth and used the Wyeth identity more prominently across its global operations.
Aftermath
The renaming strengthened the visibility of the Wyeth identity before the company was acquired by Pfizer.
Recent events
- 2012
Nestlé acquires Pfizer Nutrition[3]
M&A
Nestlé acquired Pfizer's infant-nutrition business, including the former Wyeth nutrition operations, subject to applicable regulatory approvals.
- 2009
Pfizer agrees to acquire Wyeth[5]
M&A
Pfizer announced an agreement to acquire Wyeth in a transaction that combined two major American pharmaceutical companies and expanded Pfizer's presence in vaccines, biologics, consumer health and nutrition.
- 2009
Pfizer completes acquisition of Wyeth[2]
M&A
The acquisition closed, ending Wyeth's status as an independent public company and integrating its operations into Pfizer.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/惠氏-wyeth · Editorial policy · How profiles are compiled